# MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma

> **NCT01443065** · PHASE2 · COMPLETED · sponsor: **UNICANCER** · enrollment: 162 (actual)

## Conditions studied

- Malignant Neoplasm of Esophagus
- Malignant Neoplasm of Stomach

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Folinic Acid
- **DRUG:** 5-fluoro-uracil
- **DRUG:** panitumumab
- **DRUG:** AMG102

## Key facts

- **NCT ID:** NCT01443065
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2014-03
- **Final completion:** 2018-09
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2020-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01443065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01443065, "MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01443065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*